Is allogeneic stem cell transplantation for myelofibrosis still indicated at the time of molecular markers and JAK inhibitors era?

Elsa LestangPierre PeterlinYannick Le BrisViviane DubruilleJacques DelaunayCatherine GodonOlivier TheisenNicolas BlinBeatrice MaheThomas GastinneAlice GarnierCyrille TouzeauMaud VoldoireMarie C BeneSteven Le GouillNoel MilpiedMohamad MohtyPhillipe MoreauThierry GuillaumePatrice Chevallier

Published in: European journal of haematology (2017)

Not all intermediate-2/high-risk DIPSS+ MF patients benefit from ASCT, especially since the introduction of JAK2 inhibitors.

Keyphrases

stem cell transplantation
high dose
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
low dose
bone marrow
patient reported outcomes
single molecule